Opthea Limited (OPT)
3.82
0.28 (7.91%)
At close: Jan 14, 2025, 3:53 PM
3.82
0.00%
After-hours Jan 14, 2025, 03:53 PM EST
undefined% (undefined)
| Bid | 3.61 |
| Market Cap | 4.86B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.76 |
| PE Ratio (ttm) | -1.38 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 6.15 |
| Volume | 32,101 |
| Avg. Volume (20D) | 22,488 |
| Open | 3.65 |
| Previous Close | 3.54 |
| Day's Range | 3.65 - 3.89 |
| 52-Week Range | 1.79 - 5.45 |
| Beta | undefined |
About OPT
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 16, 2020
Employees 33
Stock Exchange NASDAQ
Ticker Symbol OPT
Website https://www.opthea.com
Analyst Forecast
According to 1 analyst ratings, the average rating for OPT stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 214.14% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
1 week ago ·
Source
+4.34%
Opthea Limited shares are trading higher after the...
Unlock content with
Pro Subscription
